tiprankstipranks
Advertisement
Advertisement

MOLN Stock Latest News

Molecular Partners Adds Deal Veteran to Board as Shareholders Back All AGM Proposals
Company AnnouncementsMolecular Partners Adds Deal Veteran to Board as Shareholders Back All AGM Proposals
3d ago
6K
MOLN
Molecular Partners Sets 2026 AGM, Nominates Clare Fisher to Board as Long-Serving Director Steps Down
PremiumCompany Announcements
Molecular Partners Sets 2026 AGM, Nominates Clare Fisher to Board as Long-Serving Director Steps Down
18d ago
6K
MOLN
3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts
1M ago
MOLN
SVCO
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
PremiumRatings
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
1M ago
MOLN
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
PremiumRatings
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
1M ago
MOLN
Molecular Partners Posts 2025 Results, Advances Radio-DARPins and Oncology Pipeline
PremiumCompany AnnouncementsMolecular Partners Posts 2025 Results, Advances Radio-DARPins and Oncology Pipeline
1M ago
6K
MOLN
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
Premium
Ratings
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
1M ago
MOLN
Molecular Partners Publishes 2025 Report as Radio-DARPin Pipeline Enters Key Clinical Phase
Premium
Company Announcements
Molecular Partners Publishes 2025 Report as Radio-DARPin Pipeline Enters Key Clinical Phase
1M ago
6K
MOLN
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
PremiumRatings
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
2M ago
MOLN
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
PremiumThe Fly
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
2M ago
MOLN
Molecular Partners Unveils First Human Data for DLL3-Targeting Radio-DARPin MP0712 at TWC 2026
PremiumCompany Announcements
Molecular Partners Unveils First Human Data for DLL3-Targeting Radio-DARPin MP0712 at TWC 2026
2M ago
6K
MOLN
Molecular Partners presents first imaging, dosimetry data of MP0712
PremiumThe Fly
Molecular Partners presents first imaging, dosimetry data of MP0712
2M ago
MOLN
Molecular Partners initiated with a Buy at H.C. Wainwright
PremiumThe FlyMolecular Partners initiated with a Buy at H.C. Wainwright
3M ago
MOLN
Molecular Partners Launches New Clinical Trials and Maps 2026 Milestones Ahead of J.P. Morgan Healthcare Conference
Premium
Company Announcements
Molecular Partners Launches New Clinical Trials and Maps 2026 Milestones Ahead of J.P. Morgan Healthcare Conference
3M ago
6K
MOLN
Molecular Partners provided update on latest progress, 2026 milestones
Premium
The Fly
Molecular Partners provided update on latest progress, 2026 milestones
3M ago
MOLN
Molecular Partners forms Scientific Advisory Board
PremiumThe Fly
Molecular Partners forms Scientific Advisory Board
4M ago
MOLN
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
PremiumRatings
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
4M ago
MOLN
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
PremiumThe Fly
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
4M ago
MOLN
Molecular Partners Presents Promising MP0533 Trial Data at ASH Meeting
PremiumCompany Announcements
Molecular Partners Presents Promising MP0533 Trial Data at ASH Meeting
4M ago
6K
MOLN
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
PremiumThe FlyMolecular Partners price target lowered to $3.75 from $4 at JPMorgan
4M ago
MOLN
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
Premium
The Fly
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
4M ago
MOLN
Buy Rating for Molecular Partners: Innovative Pipeline and Promising SCLC Advancements
Premium
Ratings
Buy Rating for Molecular Partners: Innovative Pipeline and Promising SCLC Advancements
5M ago
MOLN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >